Evidence linking GlaxoSmithKline's swine flu vaccine to narcolepsy has mounted up this year, with new findings from Finland, Sweden and the United Kingdom emerging. Now, having previously knocked back compensation claims, the data has prompted the U.K. government to accept the link.
From 2009 to 2011, 25 adults developed narcolepsy in Finland, 18 of whom had received GSK's swine flu vaccine, Pandemrix.
A month after the European Medicines Agency said there was insufficient evidence of the link between the sleep disorder narcolepsy and children being vaccinated with GlaxoSmithKline's ($GSK) Pandemrix vaccine, another study says it is so.
For years now, evidence has been mounting that a GlaxoSmithKline flu vaccine may have caused narcolepsy in nearly 800 Europeans who received the shot. Now the jab's adjuvant--designed to boost the potency of the vaccine--is under the microscope as the potential cause of the spike in cases of the sleeping disorder.
The European Medicines Agency began a review of the vaccine's safety in 2010. On Friday, the agency announced that evidence presented so far does not lead to any new concerns regarding the safety of the vaccine.
Regulators on both sides of the Atlantic issued a slew of decrees about drug safety, weighing in on everything from flu vaccine to bone drugs to Pfizer's smoking cessation med Chantix. The biggest
The World Health Organization is widening its probe of a possible link between GlaxoSmithKline's Pandemrix vaccine and narcolepsy. In an advisory panel briefing, Reuters reports, the agency said
As 12 nations have reported suspected cases of narcolepsy linked to swine flu vaccination, World Health Organization scientists are saying more investigation is warranted. However, the health body
Finland's National Institute for Health and Welfare says there is a link between GlaxoSmithKline's Pandemrix flu vaccine and a spike in narcolepsy cases. Narcolepsy is a disorder that causes a person
GlaxoSmithKline's ($GSK) Pandemrix swine flu vaccine produced a swifter, stronger immune response and was likely to offer better protection than one produced by rival Baxter ($BAX), according to a